(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 13.07% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Ani Pharmaceuticals's revenue in 2025 is $674,068,000.On average, 6 Wall Street analysts forecast ANIP's revenue for 2025 to be $18,211,188,755, with the lowest ANIP revenue forecast at $18,100,712,886, and the highest ANIP revenue forecast at $18,496,476,438. On average, 7 Wall Street analysts forecast ANIP's revenue for 2026 to be $19,590,924,042, with the lowest ANIP revenue forecast at $19,097,161,896, and the highest ANIP revenue forecast at $19,954,974,522.
In 2027, ANIP is forecast to generate $21,146,207,652 in revenue, with the lowest revenue forecast at $20,121,771,422 and the highest revenue forecast at $21,960,003,226.